Bezielle: Phase Ib data

In a U.S. Phase Ib trial in 27 patients, Bezielle produced 6 cases of stable disease, including 3 cases lasting >120 days. The MTD was twice-daily 20 g Bezielle. Data were published in Breast Cancer R...